Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Valeo Pharma Inc (EM) VPHIF

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and... see more

Current News (EXPM:VPHIF)

Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.

Canada NewsWire February 6, 2025

Canadian Investment Regulatory Organization Trading Halt - VPH

Canada NewsWire October 2, 2024

VALEO PHARMA INITIATES RESTRUCTURING PROCEEDINGS UNDER THE CCAA TO IMPLEMENT A REVIEW OF ITS STRATEGIC ALTERNATIVES

Canada NewsWire October 1, 2024

VALEO PHARMA REPORTS THIRD QUARTER 2024 REVENUES

Canada NewsWire September 12, 2024

VALEO PHARMA TO HOST THIRD QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST

Canada NewsWire September 9, 2024

VALEO PHARMA AMENDS CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP

Canada NewsWire September 3, 2024

VALEO PHARMA ANNOUNCES VOLUNTARY DELISTING FROM OTCQB VENTURE MARKET

Canada NewsWire August 29, 2024

VALEO PHARMA ANNOUNCES LEADERSHIP CHANGES

Canada NewsWire August 6, 2024

VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE

Canada NewsWire June 18, 2024
View More News ››

Opinion & Analysis (EXPM:VPHIF)

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

Nico Popp December 9, 2020

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

Stockhouse Editorial September 29, 2020

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

Stockhouse Editorial September 23, 2020

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

Stockhouse Editorial September 11, 2020

Desert Gold, dynaCERT, Valeo Pharma - good news and the right time

Stockhouse Editorial September 3, 2020

Valeo Pharma In-Play, New HesperCo™ Immune System Support Scientifically Demonstrated

Stockhouse Editorial September 2, 2020
View More Opinion ››

Bullboard Posts (EXPM:VPHIF)

Fourth Quarter and year-end 2023 Webcast and Conference Call

Valeo will host a conference call to discuss its fourth quarter and year-end 2023 results and highlights on Tuesday January 30...
Betteryear2 - January 29, 2024

VALEO PHARMA REPORTS RECORD ANNUAL REVENUES

Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of $13.1 million for Q4-23, up 4...
Betteryear2 - January 29, 2024

VPH

Interesting opportunityi high revenue high expenses. See where this sits next spring could be a nice play here at these levels
Bluechips19 - November 22, 2023

UPDATE ON OPHTHALMOLOGY BUSINESS UNIT T.VPH

Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Baucsh + Lomb SIMBRINZA®...
Betteryear2 - July 4, 2023

VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES

VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES - Valeo Pharma
NonoRobotSG - June 15, 2023

VPH: To profit from forest fires!

VPH sells products with a focus on Respiratory/Allergy.
Royal10 - June 6, 2023
View more Bullboard ››

Silver North Resources Ltd.

Silver North Resources Ltd.

Silver North Resources Ltd., an exploration stage company, acquires and explores mineral properties. It explores for gold ...
View More »

Podcasts